Virus and supercharged immune cells attack tough melanoma
NCT ID NCT06961786
Summary
This early-stage study is testing a new combination treatment for advanced melanoma that has not responded to other therapies. It uses a modified virus designed to infect and kill cancer cells, combined with the patient's own tumor-fighting immune cells and a short course of chemotherapy. The main goal is to see if this three-part approach is safe and tolerable for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University
Copenhagen, Denmark
Conditions
Explore the condition pages connected to this study.